Why Did the Stock Market Shun Bristol-Myers $74B Deal for Celgene?

TL;DR

Bristol Myers acquires Celgene for $74 billion, causing stock fluctuations and speculations.

Transcript

Chris Hill: The deal of the day is Celgene and Bristol Myers. Bristol Myers, one of the big pharma companies, buying Celgene, one of the big biotech companies, to the tune of $74 billion. Celgene shareholders -- I believe you are one? Bill Barker: Yes, I am. Full disclosure. Hill: Here's what you're going to get in this deal. You're going to get on... Read More

Key Insights

• 🤝 Shareholders receive one share of Bristol Myers stock and $50 cash per Celgene share in the $74 billion acquisition deal.
• 😮 Post-acquisition, Bristol Myers' stock declines by about 12%, while Celgene's stock rises by 25%.
• 💡 Speculations arise around potential overpayment, previous struggles, and failed bid expectations influencing Bristol Myers' stock performance.
• 😀 Shareholders face decisions on whether to retain Bristol Myers' shares post-acquisition based on market sentiments and long-term prospects.
• ⛩️ Discussions on potential rebranding following the acquisition hint at possible image and marketing strategy changes for Bristol Myers-Celgene.
• 📈 Market reactions reflect the traditional pattern of acquiring company declines with acquired company gains, in contrast to recent market trends.
• 🤝 Conversations regarding shareholder decisions, rebranding, and strategic implications take place amidst the acquisition deal at Bristol Myers-Celgene headquarters.

Questions & Answers

Q: How does the acquisition of Celgene by Bristol Myers impact shareholders?

Shareholders receive one share of Bristol Myers stock and $50 cash per Celgene share, leading to stock price fluctuations and decisions on holding or selling.

Q: What factors contribute to Bristol Myers' stock decline post-acquisition?

Factors such as perceived overpayment, existing company struggles, and potential failed bid expectations from Pfizer contribute to Bristol Myers' stock decline.

Q: What considerations are involved in shareholder decisions post-acquisition?

Shareholders must weigh the market sentiment, potential rebranding outcomes, and long-term prospects of both Bristol Myers and Celgene shares post-acquisition.

Q: How does potential rebranding as a result of the acquisition impact Bristol Myers?

Potential rebranding discussions following the acquisition may impact Bristol Myers' image and marketing strategies, with shareholder reactions playing a significant role in the decision-making process.

Summary & Key Takeaways

• Bristol Myers acquires Celgene for $74 billion, offering one share of Bristol Myers stock and $50 cash for each Celgene share.

• Stock prices fluctuate post-announcement, with Bristol Myers declining and Celgene rising.

• Speculations arise on shareholder decisions and potential rebranding post-acquisition.